Hematology

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Podcasts Q&As
Interactive
Polls Quizzes
Events & Education
ASH Annual Meeting

FDA Alerts

FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA Phone screen
FDA Approval
Tecartus (brexucabtagene autoleucel) Receives FDA Approval for Relapsed or Refractory Mantle Cell Lymphoma
04/15/2026
Anthony Calabro, MA
The FDA has granted full approval for the use of brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma, based on confirmatory ZUMA-2 data.
04/15/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026
FDA Approval
FDA sign
FDA Approval
FDA Approves Orforglipron (Foundayo) for Chronic Weight Management
04/02/2026
Anthony Calabro, MA
The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.
04/02/2026